June 25, 2024 04:16 PM EDTUpdated 04:40 PM

Arrowhead shelves one cardiometabolic drug candidate, focuses on another

Nicole DeFeudis

Editor

On Tuesday, Arrowhead Pharmaceuticals said it will shift focus to its experimental cardiometabolic drug plozasiran and will deprioritize its work on zodasiran, emphasizing the need …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Arrowhead shelves one cardiometabolic drug candidate, focuses on another

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

Novo Nordisk to decrease some insulin pen manufacturing, transition supply

Exclusive: J&J folds cardiovascular and metabolic drug unit

FDA approves Dupixent in COPD, opening ‘next chapter’ for Sanofi and Regeneron’s bestseller

FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatry

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

Ar­row­head shelves one car­diometa­bol­ic drug can­di­date, fo­cus­es on an­oth­er

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Arrowhead shelves one cardiometabolic drug candidate, focuses on another